$5.38
0.37% today
Nasdaq, Sep 23, 04:49 pm CET
ISIN
NL0015436031
Symbol
CVAC

CureVac N.V. Stock price

$5.36
-0.08 1.47% 1M
+2.36 78.67% 6M
+1.95 57.18% YTD
+2.27 73.46% 1Y
-2.19 29.01% 3Y
-44.64 89.28% 5Y
-50.54 90.41% 10Y
-50.54 90.41% 20Y
Nasdaq, Closing price Mon, Sep 22 2025
+0.01 0.19%
ISIN
NL0015436031
Symbol
CVAC
Industry

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$782.4m
Net debt
positive
Cash
$467.0m
Shares outstanding
225.2m
Valuation (TTM | estimate)
P/E
5.3 | negative
P/S
2.0 | 14.5
EV/Sales
1.3 | 9.4
EV/FCF
3.4
P/B
1.7
Financial Health
Equity Ratio
86.8%
Return on Equity
23.3%
ROCE
33.5%
ROIC
79.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$602.3m | $83.1m
EBITDA
$268.9m | $-119.9m
EBIT
$245.6m | $-148.4m
Net Income
$228.5m | $-127.8m
Free Cash Flow
$231.4m
Growth (TTM | estimate)
Revenue
675.1% | -86.8%
EBITDA
184.9% | -151.6%
EBIT
171.8% | -170.8%
Net Income
169.5% | -166.8%
Free Cash Flow
159.4%
Margin (TTM | estimate)
Gross
94.8%
EBITDA
44.6% | -144.3%
EBIT
40.8%
Net
37.9% | -153.7%
Free Cash Flow
38.4%
More
EPS
$1.0
FCF per Share
$1.0
Short interest
0.8%
Employees
904
Rev per Employee
$700.0k
Show more

Is CureVac N.V. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

CureVac N.V. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a CureVac N.V. forecast:

6x Buy
46%
7x Hold
54%

Analyst Opinions

13 Analysts have issued a CureVac N.V. forecast:

Buy
46%
Hold
54%

Financial data from CureVac N.V.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
602 602
675% 675%
100%
- Direct Costs 31 31
83% 83%
5%
571 571
613% 613%
95%
- Selling and Administrative Expenses 87 87
1% 1%
14%
- Research and Development Expense 186 186
47% 47%
31%
269 269
185% 185%
45%
- Depreciation and Amortization 23 23
9% 9%
4%
EBIT (Operating Income) EBIT 246 246
172% 172%
41%
Net Profit 228 228
170% 170%
38%

In millions USD.

Don't miss a Thing! We will send you all news about CureVac N.V. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

CureVac N.V. Stock News

Neutral
Accesswire
about one month ago
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all shares of CureVac, uniting two highly complementary German companies to bring transformative mRNA-based treatments to patients globally Entered into agreements to resolve and dismiss all pen...
More CureVac N.V. News

Company Profile

CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Head office Netherlands
CEO Alexander Zehnder
Employees 904
Founded 2020
Website www.curevac.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today